Vertex Pharmaceuticals Incorporated

Informe acción NasdaqGS:VRTX

Capitalización de mercado: US$116.0b

Vertex Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Vertex Pharmaceuticals de 47.4% y 8.7% por año respectivamente. Se prevé que el BPA crezca en un 47% al año. Se espera que la rentabilidad financiera sea de 30.6% en 3 años.

Información clave

47.4%

Tasa de crecimiento de los beneficios

47.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs28.4%
Tasa de crecimiento de los ingresos8.7%
Rentabilidad financiera futura30.6%
Cobertura de analistas

Good

Última actualización22 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:VRTX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202612,9244,9125,4605,87324
12/31/202511,8114,2824,7565,38833
12/31/202410,892-46851130731
9/30/202410,626-480-1,351-843N/A
6/30/202410,337-490-1,426-944N/A
3/31/202410,1854,0193,4793,944N/A
12/31/20239,8693,6203,2793,537N/A
9/30/20239,6543,4704,2054,381N/A
6/30/20239,5053,3653,8794,068N/A
3/31/20239,2083,2603,8904,074N/A
12/31/20228,9313,3223,9254,130N/A
9/30/20228,7013,2733,8144,047N/A
6/30/20228,3503,1953,7874,018N/A
3/31/20227,9482,4512,4512,679N/A
12/31/20217,5742,3422,4092,644N/A
9/30/20217,1302,1761,9192,140N/A
6/30/20216,6841,9921,7772,121N/A
3/31/20216,4152,7623,0483,359N/A
12/31/20206,2062,7122,9943,254N/A
9/30/20205,9912,6912,9793,208N/A
6/30/20205,4032,0812,5572,635N/A
3/31/20204,8191,5111,9832,060N/A
12/31/20194,1631,1771,4941,569N/A
9/30/20193,6202,1441,3631,438N/A
6/30/20193,4542,2151,4131,484N/A
3/31/20193,2652,1551,2581,342N/A
12/31/20183,0482,0961,1751,270N/A
9/30/20182,8296471,0601,183N/A
6/30/20182,623415N/A972N/A
3/31/20182,415226N/A832N/A
12/31/20172,489263N/A845N/A
9/30/20172,296196N/A762N/A
6/30/20172,131259N/A658N/A
3/31/20172,019177N/A517N/A
12/31/20161,702-112N/A236N/A
9/30/20161,661-219N/A121N/A
6/30/20161,557-275N/A-7N/A
3/31/20161,292-399N/A-158N/A
12/31/20151,032-556N/A-365N/A
9/30/2015759-659N/A-576N/A
6/30/2015628-734N/A-602N/A
3/31/2015600-704N/A-620N/A
12/31/2014580-738N/A-573N/A
9/30/2014787-582N/A-362N/A
6/30/2014830-530N/A-289N/A
3/31/20141,002-428N/A-162N/A
12/31/20131,212-504N/A-61N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VRTX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que VRTX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que VRTX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (8.7% al año) de VRTX crezcan más despacio que el mercado de US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.7% al año) de VRTX crezcan más despacio que 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de VRTX sea alta dentro de 3 años (30.6%)


Descubre empresas en crecimiento